Abstract
For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 383-389 |
| Number of pages | 7 |
| Journal | Biomedicine and Pharmacotherapy |
| Volume | 61 |
| Issue number | 7 |
| DOIs | |
| State | Published - Aug 2007 |
Fingerprint
Keywords
- Albumin-bound fraction
- Biomarkers
- MALDI O-TOF
- Parkinson's disease
ASJC Scopus subject areas
- Pharmacology
Cite this
Serum biomarkers for Alzheimer's disease : Proteomic discovery. / German, Dwight C.; Gurnani, Prem; Nandi, Animesh; Garner, Harold R.; Fisher, Wayne; Diaz-Arrastia, Ramon; O'Suilleabhain, Padraig; Rosenblatt, Kevin P.
In: Biomedicine and Pharmacotherapy, Vol. 61, No. 7, 08.2007, p. 383-389.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Serum biomarkers for Alzheimer's disease
T2 - Proteomic discovery
AU - German, Dwight C.
AU - Gurnani, Prem
AU - Nandi, Animesh
AU - Garner, Harold R.
AU - Fisher, Wayne
AU - Diaz-Arrastia, Ramon
AU - O'Suilleabhain, Padraig
AU - Rosenblatt, Kevin P.
PY - 2007/8
Y1 - 2007/8
N2 - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.
AB - For Alzheimer's disease (AD), the most common neurodegenerative disease, there is no simple, cost-effective biomarker for disease identification. Using novel mass spectrometry (MS)-based techniques, and analysis of the albumin-enriched low molecular weight proteome, minute amounts of human serum were analyzed for the measurement of thousands of peptides and proteins in parallel. The mass spectrograms were then evaluated with a novel computer algorithm to identify spectral peaks that discriminate between samples from patients with and without AD. There are four peaks that distinguish AD from control subjects and AD subjects from those with Parkinson's disease (PD). Additionally, after analyzing data from a recently published study of AD and control subjects, we found three discriminating peaks in common with the four from our patient serum samples. The identification of these peptides/proteins, and their direct measurement in patient serum, may allow the development of a simple, cost-effective test for AD.
KW - Albumin-bound fraction
KW - Biomarkers
KW - MALDI O-TOF
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=34547813002&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34547813002&partnerID=8YFLogxK
U2 - 10.1016/j.biopha.2007.05.009
DO - 10.1016/j.biopha.2007.05.009
M3 - Article
C2 - 17614251
AN - SCOPUS:34547813002
VL - 61
SP - 383
EP - 389
JO - Biomedicine and Pharmacotherapy
JF - Biomedicine and Pharmacotherapy
SN - 0753-3322
IS - 7
ER -